56 results about "Choleretic" patented technology

The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and / or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).

The invention provides a probiotic composite composition containing bifidobacterium and lactobacillus acidophilus and application of the probiotic composite composition. The probiotic composite composition is prepared from the following components in parts by weight: 0.2 to 0.8 part by weight of probiotics, 0.1 to 0.7 part by weight of inulin and 1.5 to 2.7 parts by weight of soluble dietary fiber. The probiotic composite composition provided by the invention is a composite intestinal health nutrient product; the number of viable bacteria is not attenuated along with time; a flora has good acid resistance and bile resistance; the probiotic composite composition has clinically-verified health efficacy; for a 28-unit type probiotic composite preparation, each unit contains the probiotic composite composition and a description; the probiotic composite composition is used for crowds with constipation, ozostomia and skin problem and crowds taking antibiotics; according to the probiotic composite composition, constipation and ozostomia symptoms of the crowds can be improved, the skin type is improved, side effects of the antibiotics are reduced, and the life quality of the crowds is improved.

The invention discloses a traditional Chinese medicine composition for treating an autoimmune liver disease, and a preparation method thereof. The traditional Chinese medicine composition comprises the following medicinal raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-30 parts of cooked rhubarb, 10-30 parts of glossy privet fruit, 10-30 parts of radix curcumae, 10-30 parts of large-leaved gentian, 10-30 parts of caulis spatholobi, 10-30 parts of caulis sinomenii, 10-30 parts of radix rubiae, 10-30 parts of sedum sarmentosum and 5-15 parts of liquorice. The traditional Chinese medicine has the effects of strengthening body resistance, detoxifying, dispersing stagnated liver qi for promoting bile flow, promoting blood circulation to remove blood stasis, expelling wind and removing dampness; the main treatment range comprises autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and overlap syndrome of any two in the three diseases; and the traditional Chinese medicine composition has the treatment effects of restoring immune balance, inhibiting liver inflammation, protecting liver function, resisting hepatic fibrosis, improving clinical symptoms, improving survival quality and the like, and has high safety.

The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, M1, M2, m, n, Q, L, ring A, ring B and ring C are as defined in the specification. The invention further relates to a preparation method of the compounds, and application in preparing medicines for treating and / or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication and malignant tumors mediated by an FXR. The formula (I) is shown in the description.

The invention discloses a Chinese medicine composition for treating an autoimmune liver disease. The Chinese medicine composition is prepared from the Chinese medicinal materials, namely rheum officinale, radix rubiae, fructus forsythia, herba siegesbeckiae, large-leaved gentian and liquorice. The invention also discloses a preparation method of the Chinese medicine composition and application of the Chinese medicine composition. The composition has the effects of clearing away heat and toxic materials, smoothing liver-gallbladder, and promoting blood circulation to remove blood stasis, and is mainly used for treating autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.

The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, R4, W, A, Z, E, X, Y and n are as defined in the specification and the claims. The invention further relates to a preparation method of the compounds, pharmaceutical preparation and application in preparing medicines for treating and / or preventing related diseases such as non-alcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorders, diabetic complication andmalignant tumors mediated by an FXR. The formula (I) is shown in the description.

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and / or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(tri-fluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC). In some embodiments, the methods further comprise administering Compound 1, or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and / or vitamin D supplement, and vitamin A, D, E and / or K supplement. Other embodiments, relate to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC).

The invention relates to application of a polypeptide compound having a double activation effect on a glucagons-like peptide-1 receptor (GLP-1R) and a glucagons receptor (GCCR). The degree of BDL-induced rat cholestasis-induced liver fibrosis can be obviously decreased, and the effect of treating biliary cirrhosis and other diseases is remarkable. The double-target-point agonist polypeptide can beused for preventing or treating biliary cirrhosis and related liver fibrosis diseases.

The invention relates to an application of an encoding gene ESRRA of an estrogen-related receptor alpha (ERR alpha) in preparation of a medicine for preventing or treating liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The adeno-associated virus is utilized to construct an ERRalpha overexpression vector system, and the fact that the ERR alpha gene and a delivery system of the ERR alpha gene can be used for preventing or treating the liver diseases is proved on various disease models.

The invention relates to a traditional Chinese medicinal composition for treating primary biliary cirrhosis and a preparation method thereof. The traditional Chinese medicinal composition can be used for effectively solving the problems of poor and unstable curative effect, toxic and side effects and easy recurrence and is prepared from the following raw materials in parts by weight: 500-1500 parts of bupleurum, 300-800 parts of chinaroot greenbrier, 500-1500 parts of radix ranunculi ternati, 1000-2000 parts of madder, 300-500 parts of leech, 500-1000 parts of earthworm and 500-1500 parts of liquorice. The traditional Chinese medicinal composition provided by the invention has the main effects of clearing away heat and toxic materials, soothing the liver and gallbladder and promoting blood circulation to remove blood stasis, is good at treating the primary biliary cirrhosis with liver and gallbladder stasis, dampness-heat stay inside and qi stagnation and blood stasis syndromes, adopts liver and gallbladder soothing, blood circulation promoting and blood stasis removing as main therapies, integrates pharmaceutical effects of soothing gallbladder, promoting menstruational flow and regulating flow of qi and combined action of main and collateral channels into a whole and has high significant efficiency and effective rate, stable curative effect, no recurrence, small side effect and low cost.

An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.

The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg / day and / or spironolactone >100 mg / day or equivalent doses of an alternative loop-acting and / or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

The invention discloses a molecular marker for diagnosing primary biliary cholangitis and application thereof. According to the present invention, the anti-human multimer immunoglobulin receptor antibody is adopted as the primary biliary cholangitis diagnosis molecular marker so as to prepare the diagnosis reagent; the human multimer immunoglobulin receptor antibody is remarkably increased in serum of PBC AMA-M2 subtype positive and negative patients, which indicates that in the attack of PBC, the serum anti-human multimer immunoglobulin receptor antibody specifically targets human multimer immunoglobulin receptors on small and medium bile ducts in the liver, thereby causing damage to the small and medium bile ducts. According to the invention, a new explanation is provided for the pathogenesis of the PBC, and in addition, a new means is provided for the specific diagnosis of the PBC by detecting the level of the serum anti-human multimeric immune globulin receptor antibody. The method is simple and reliable, materials are convenient to obtain, and the method has great application value in PBC diagnosis.

The invention provides mebendazole for use in the treatment or prophylaxis of a chronic inflammatory disease, and in particular wherein the chronic inflammatory disease is an autoimmune disease, for example sarcoidosis, systemic lupus erythematosus (SLE), Huntington's disease, end stage renal disease, systemic sclerosis (also called scleroderma), myositis, diabetes type 1, multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, psoriasis, primary biliary cirrhosis, autoimmune hepatitis, Graves' disease, Addison's disease, tuberculosis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, Alzheimer's disease and coeliac disease. A method for the treatment or prophylaxis of a chronic inflammatory disease, comprising administering an effective amount of a mebendazole or a pharmaceutical composition of mebendazole is also provided. The use of mebendazole for the manufacture of a medicament for the treatment of a chronic inflammatory disease is also provided.

The invention provides choleretic Chinese patent medicine which is prepared from radix curcumae, endothelium corneum gigeriae galli, aloe, black alum, potassium nitrate and fresh pig's bile. The choleretic Chinese patent medicine is quick in action, good in treatment effect, less prone to causing recurrence and convenient to eat, operational risk is avoided, the preparation process is simple, and the choleretic Chinese patent medicine is suitable for mass production and wide popularization.

The invention discloses a directional separation method for immune adjustment intestinal lactobacillus, and belongs to the technical field of biological preparations. A biotinylated IgA antibody is used for treating animal or human saliva, intestinal contents or fecal bacterial suspension, streptavidin magnetic nano-beads are used for separation, and enrichment culture and selective separation are performed to obtain the intestinal lactobacillus with an immune adjustment function. Compared with a traditional method, the method can rapidly and directionally separate immune adjustment beneficial bacteria, and obtained strains can be used for feed, common food or functional food after acid resistance, bile resistance and adhesion of the strains are further verified.

Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; or liver damage arising from fibrosis.

The invention belongs to the technical field of medicine, and specifically relates to compounds represented by formula (I), pharmaceutically acceptable salts, esters or stereoisomers thereof, R 1 , R 2 , R 3 , R 4 , W, A, Z, E, X, Y, n are as defined in the description and claims; the present invention also relates to the preparation methods, pharmaceutical preparations and preparation of these compounds for the treatment and / or prevention of FXR receptor The application of drugs in related diseases such as non-alcoholic fatty liver, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications and malignant tumors.

The invention belongs to the field of medical detection, and relates to a serum exosome PIGR, specifically to a use for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitisand predicting curative effect. The technical solution adopted by the invention is a kit for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitis and predicting curative effect, which is characterized by including the following components: a pIgR standard, a polystyrene ELISA (Enzyme Linked Immunosorbent Assay) microplate coated with pIgR antigens, a second enzyme-labeled antibody, a sample diluent, and an auxiliary reagent. The technical solution of the application method of the kit includes the following steps of: (1) preparing the sample diluent; (2) diluting thepIgR standard with a BSA-PBS solution into 8 gradients; (3) adding the standard and the sample diluent to a microplate; (4) adding the second enzyme-labeled antibody to each well; (5) adding a color developing liquid to each well; and (6) using a microplate reader to read an OD value at a wavelength of 450 nm , drawing a standard curve, and converting pIgR concentration in the sample. New kits andapplications are implemented by employing the above schemes.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

Disclosed are antagonists of PC3-secreted microprotein (PSMP) and use of the antagonists for treatment of liver, lung, or kidney fibrosis, including various diseases or disorders associated with liver, lung, or kidney fibrosis such as, e.g., non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), drug-induced lung injury, acute kidney injury (AKI), chronic kidney disease (CKD), lupus nephritis, IgA nephropathy, and membranous glomerulonephritis. Also disclosed are PSMP antagonists and their use for treatment of graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE). Suitable PSMP antagonists for use in disease treatment include PSMP-binding proteins such as, for example, neutralizing anti-PSMP antibodies.

The invention relates to a biomarker for diagnosing primary sicca syndrome and application of the biomarker. According to the biomarker for diagnosing primary sicca syndrome and application of the biomarker of the invention, a lectin microarray containing 56 types of lectins is adopted to detect a glycan spectrum of specific binding of the serum IgG and the lectin of a patient with the primary sicca syndrome (PSS). The results show that LCA lectin binding glycan content is increased in the patient with primary biliary cholangitis (PBC) compared with that of a healthy person. As the LCA lectin is specific binding fucose, the expression of the fucose level in the patient withPSS is increased. A lectin immunoblotting verification result shows that the content of the LCA lectin binding glycan is still increased in the patient with the PSS. Therefore, the LCA lectin binding glycan level in the serum IgG can be used as a marker of the primary sicca syndrome (PSS).

An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.

The invention discloses application of polypeptide AT03 in a medicine used for treating primary biliary cholangitis. The amino acid sequence of the polypeptide AT03 is Val-His-Val-Val-R1, wherein R1 is -NH2. A large number of experimental studies prove that the polypeptide AT03 has a treatment effect on a common bile duct-ligated rat cholestatic liver cirrhosis model, and the treatment effect is specifically shown in that liver cholestasis, intrahepatic biliary obstruction, liver cell injury and liver tissue fibrosis process can be improved; and the polypeptide AT03 can be used for preparing the medicine used for treating primary biliary cholangitis.

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

The invention relates to a traditional Chinese medicine compound preparation with effects of benefiting gallbladder and harmonizing stomach, and invigorating blood circulation and eliminating dampness and a use thereof. The traditional Chinese medicine compound preparation is prepared from rhizoma panacis japonica, gentrin knotweed, processed rhizoma pinelliae, loquat leaf, poria cocos, lily and radish seeds. The traditional Chinese medicine compound preparation has effects of benefiting gallbladder and harmonizing stomach, and invigorating blood circulation and eliminating dampness. A pharmacological study proves that the traditional Chinese medicine compound preparation can be used for treating chronic gastritis such as chronic superficial gastritis, bile reflux gastritis and atrophic gastritis, has definite therapeutic effects, no toxic or side effect and a low cost and is suitable for promotion and application.